{"id":46289,"date":"2025-11-11T11:09:49","date_gmt":"2025-11-11T03:09:49","guid":{"rendered":"https:\/\/flcube.com\/?p=46289"},"modified":"2025-11-11T11:09:50","modified_gmt":"2025-11-11T03:09:50","slug":"cansinobio-licenses-isl%e2%80%913c%e2%80%91lnp-platform-to-panru-biotech-100-m-deal-to-accelerate-mrna-cancer-vaccines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46289","title":{"rendered":"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines"},"content":{"rendered":"\n<p><strong>CanSino Biologics Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6185:HKG\">HKG: 6185<\/a>) announced today a <strong>licensing agreement<\/strong> with <strong>PanRu Biotechnology (Tianjin) Co., Ltd.<\/strong> (\u201cPanRu Biotech\u201d). The contract grants PanRu the right to use CanSino\u2019s <strong>independently developed three\u2011component lipid nanoparticle delivery system (ISL\u20113C\u2011LNP)<\/strong> for its <strong>therapeutic mRNA vaccine program (PRBT001) targeting prostate cancer<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-economics\">Deal Economics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensee<\/strong><\/td><td>PanRu Biotechnology (Tianjin) Co., Ltd.<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>CanSino Biologics Inc.<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>ISL\u20113C\u2011LNP (three\u2011component ionizable sterol lipid system)<\/td><\/tr><tr><td><strong>Up\u2011front \/ Milestone Payments<\/strong><\/td><td>&gt;\u202fRMB\u202f100\u202fmillion (\u2248\u202fUS$14\u202fmillion) over the next several years<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Global R&amp;D, manufacturing, and commercialization of PRBT001 mRNA vaccine<\/td><\/tr><tr><td><strong>Effective Date<\/strong><\/td><td>11\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Expand ISL\u20113C\u2011LNP applications; generate recurring revenue; strengthen mRNA pipeline collaborations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-spotlight-isl-3c-lnp\">Technology Spotlight \u2013 ISL\u20113C\u2011LNP<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Innovation:<\/strong> Built on <strong>ionizable sterol lipid (ISL) compounds<\/strong>, the <strong>three\u2011component system<\/strong> bypasses the <strong>patent barrier<\/strong> that limits conventional <strong>four\u2011component LNPs (4C\u2011LNPs)<\/strong>.<\/li>\n\n\n\n<li><strong>Performance Gains:<\/strong><\/li>\n\n\n\n<li><strong>Enhanced immunogenicity<\/strong> \u2013 stronger cellular immune responses in pre\u2011clinical models.<\/li>\n\n\n\n<li><strong>Improved safety profile<\/strong> \u2013 lower reactogenicity compared with legacy LNPs.<\/li>\n\n\n\n<li><strong>Application Focus:<\/strong> Ideal for <strong>therapies requiring robust T\u2011cell activation<\/strong>, such as <strong>tumor immunotherapy<\/strong> and next\u2011generation <strong>mRNA vaccines<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-impact\">Pipeline Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program<\/th><th>Indication<\/th><th>Development Stage<\/th><th>Role of ISL\u20113C\u2011LNP<\/th><\/tr><\/thead><tbody><tr><td><strong>PRBT001 (Injection)<\/strong><\/td><td>Prostate cancer<\/td><td>Pre\u2011clinical \/ early clinical<\/td><td>Core lipid formulation for mRNA vaccine delivery<\/td><\/tr><tr><td><strong>Future mRNA candidates<\/strong><\/td><td>Various oncology &amp; infectious disease targets<\/td><td>Concept \/ early R&amp;D<\/td><td>Platform\u2011level support from CanSino\u2019s mRNA technology hub<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Collaboration History:<\/strong> The two companies previously co\u2011developed early\u2011stage data for PRBT001; the new license deepens that partnership and enables <strong>clinical data accumulation<\/strong> and <strong>global commercialization<\/strong>.<\/li>\n\n\n\n<li><strong>Support Services:<\/strong> CanSino will provide <strong>customized development, GMP manufacturing, and regulatory expertise<\/strong> to accelerate PanRu\u2019s timeline.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-strategic-implications\">Market &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Diversification:<\/strong> The <strong>RMB\u202f100\u202fmillion+<\/strong> stream adds a non\u2011dilutive revenue source for CanSino, complementing its own vaccine pipeline.<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> By offering a <strong>patent\u2011free, high\u2011performance LNP<\/strong>, CanSino positions itself as a <strong>technology licensor<\/strong> in the rapidly expanding mRNA ecosystem, potentially attracting additional partners beyond PanRu.<\/li>\n\n\n\n<li><strong>Industry Trend:<\/strong> The deal reflects a broader shift toward <strong>platform licensing<\/strong> rather than outright asset sales, allowing biotech firms to monetize IP while retaining control over core R&amp;D.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the licensing agreement, anticipated payments, and commercial prospects for the ISL\u20113C\u2011LNP platform. Actual results may differ due to risks including regulatory approvals, clinical outcomes, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46291,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,466,884,4446],"class_list":["post-46289","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-cansino-biologics","tag-hkg-6185","tag-panru-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co., Ltd. (\u201cPanRu Biotech\u201d). The contract grants PanRu the right to use CanSino\u2019s independently developed three\u2011component lipid nanoparticle delivery system (ISL\u20113C\u2011LNP) for its therapeutic mRNA vaccine program (PRBT001) targeting prostate cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46289\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines\" \/>\n<meta property=\"og:description\" content=\"CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co., Ltd. (\u201cPanRu Biotech\u201d). The contract grants PanRu the right to use CanSino\u2019s independently developed three\u2011component lipid nanoparticle delivery system (ISL\u20113C\u2011LNP) for its therapeutic mRNA vaccine program (PRBT001) targeting prostate cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46289\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T03:09:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-11T03:09:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines\",\"datePublished\":\"2025-11-11T03:09:49+00:00\",\"dateModified\":\"2025-11-11T03:09:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1101.webp\",\"keywords\":[\"Biotech\",\"CanSino Biologics\",\"HKG: 6185\",\"PanRu Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46289#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46289\",\"name\":\"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1101.webp\",\"datePublished\":\"2025-11-11T03:09:49+00:00\",\"dateModified\":\"2025-11-11T03:09:50+00:00\",\"description\":\"CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co., Ltd. (\u201cPanRu Biotech\u201d). The contract grants PanRu the right to use CanSino\u2019s independently developed three\u2011component lipid nanoparticle delivery system (ISL\u20113C\u2011LNP) for its therapeutic mRNA vaccine program (PRBT001) targeting prostate cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46289\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1101.webp\",\"width\":1080,\"height\":608,\"caption\":\"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46289#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines - Insight, China&#039;s Pharmaceutical Industry","description":"CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co., Ltd. (\u201cPanRu Biotech\u201d). The contract grants PanRu the right to use CanSino\u2019s independently developed three\u2011component lipid nanoparticle delivery system (ISL\u20113C\u2011LNP) for its therapeutic mRNA vaccine program (PRBT001) targeting prostate cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46289","og_locale":"en_US","og_type":"article","og_title":"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines","og_description":"CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co., Ltd. (\u201cPanRu Biotech\u201d). The contract grants PanRu the right to use CanSino\u2019s independently developed three\u2011component lipid nanoparticle delivery system (ISL\u20113C\u2011LNP) for its therapeutic mRNA vaccine program (PRBT001) targeting prostate cancer.","og_url":"https:\/\/flcube.com\/?p=46289","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-11T03:09:49+00:00","article_modified_time":"2025-11-11T03:09:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46289#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46289"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines","datePublished":"2025-11-11T03:09:49+00:00","dateModified":"2025-11-11T03:09:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46289"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46289#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1101.webp","keywords":["Biotech","CanSino Biologics","HKG: 6185","PanRu Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46289#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46289","url":"https:\/\/flcube.com\/?p=46289","name":"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46289#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46289#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1101.webp","datePublished":"2025-11-11T03:09:49+00:00","dateModified":"2025-11-11T03:09:50+00:00","description":"CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co., Ltd. (\u201cPanRu Biotech\u201d). The contract grants PanRu the right to use CanSino\u2019s independently developed three\u2011component lipid nanoparticle delivery system (ISL\u20113C\u2011LNP) for its therapeutic mRNA vaccine program (PRBT001) targeting prostate cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46289#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46289"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46289#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1101.webp","width":1080,"height":608,"caption":"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46289#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CanSinoBIO Licenses ISL\u20113C\u2011LNP Platform to PanRu Biotech \u2013 $100\u202fM+ Deal to Accelerate mRNA Cancer Vaccines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46289"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46289\/revisions"}],"predecessor-version":[{"id":46292,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46289\/revisions\/46292"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46291"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}